Nguyen HA, Durden DL, Lavie A. The differential ability of asparagine and glutamine in promoting the closed/active enzyme conformation rationalizes the Wolinella succinogenes L-asparaginase substrate specificity. Sci Rep. 2017 Jan 31;7:41643. doi: 10.1038/srep41643. PubMed PMID: 28139703; PubMed Central PMCID: PMC5282591.

Andrews FH, Singh AR, Joshi S, Smith CA, Morales GA, Garlich JR, Durden DL, Kutateladze TG. Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis. Proc Natl Acad Sci U S A. 2017 Feb 14;114(7):E1072-E1080. doi: 10.1073/pnas.1613091114. PubMed PMID: 28137841.

Erdreich-Epstein A, Singh AR, Joshi S, Vega FM, Guo P, Xu J, Groshen S, Ye W, Millard M, Campan M, Morales G, Garlich JR, Laird PW, Seeger RC, Shimada H, Durden DL. Association of high microvessel αvβ3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126. Oncotarget. 2016 Nov 16. doi: 10.18632/oncotarget.13386. [Epub ahead of print] PubMed PMID: 27907905.

Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma. Mol Cancer Ther. 2016 Nov;15(11):2553-2562. PubMed PMID: 27496136; PubMed Central PMCID: PMC5278767.

Singh AR, Joshi S, Zulcic M, Alcaraz M, Garlich JR, Morales GA, Cho YJ, Bao L, Levy ML, Newbury R, Malicki D, Messer K, Crawford J, Durden DL. PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma. PLoS One. 2016 Mar 3;11(3):e0150836. doi: 10.1371/journal.pone.0150836. PubMed PMID: 26938241; PubMed Central PMCID: PMC4777592.

Ishii Y, Nhiayi MK, Tse E, Cheng J, Massimino M, Durden DL, Vigneri P, Wang JY. Knockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C Release. PLoS One. 2015 Oct 16;10(10):e0140585. doi: 10.1371/journal.pone.0140585. PubMed PMID: 26473951; PubMed Central PMCID: PMC4608728.

Bhat V, Olmer M, Joshi S, Durden DL, Cramer TJ, Barnes RF, Ball ST, Hughes TH, Silva M, Luck JV, Moore RE, Mosnier LO, von Drygalski A. Vascular remodeling underlies rebleeding in hemophilic arthropathy. Am J Hematol. 2015 Nov;90(11):1027-35. doi: 10.1002/ajh.24133. PubMed PMID: 26257191; PubMed Central PMCID: PMC4618067.

Joshi S, Singh AR, Durden DL. Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma. Cancer Chemother Pharmacol. 2015 Mar;75(3):595-608. doi: 10.1007/s00280-014-2639-x. PubMed PMID: 25578041.

Singh AR, Joshi S, George E, Durden DL. Anti-tumor effect of a novel PI3-kinase inhibitor, SF1126, in (12) V-Ha-Ras transgenic mouse glioma model. Cancer Cell Int. 2014 Nov 12;14(1):105. doi: 10.1186/s12935-014-0105-9. PubMed PMID: 25425962; PubMed Central PMCID: PMC4243316.

Joshi S, Singh AR, Zulcic M, Durden DL. A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1α and HIF2α stability and tumor growth, angiogenesis, and metastasis. Mol Cancer Res. 2014 Oct;12(10):1520-31. doi: 10.1158/1541-7786.MCR-13-0682. PubMed PMID: 25103499.

Joshi S, Singh AR, Durden DL. MDM2 regulates hypoxic hypoxia-inducible factor 1α stability in an E3 ligase, proteasome, and PTEN-phosphatidylinositol 3-kinase-AKT-dependent manner. J Biol Chem. 2014 Aug 15;289(33):22785-97. doi: 10.1074/jbc.M114.587493. PubMed PMID: 24982421; PubMed Central PMCID: PMC4132784.

Joshi S, Singh AR, Zulcic M, Durden DL. A PKC-SHP1 signaling axis desensitizes Fcγ receptor signaling by reducing the tyrosine phosphorylation of CBL and regulates FcγR mediated phagocytosis. BMC Immunol. 2014 May 7;15:18. doi: 10.1186/1471-2172-15-18. PubMed PMID: 24886428; PubMed Central PMCID: PMC4017086.

Singh AR, Peirce SK, Joshi S, Durden DL. PTEN and PI-3 kinase inhibitors control LPS signaling and the lymphoproliferative response in the CD19+ B cell compartment. Exp Cell Res. 2014 Sep 10;327(1):78-90. doi: 10.1016/j.yexcr.2014.05.016. PubMed PMID: 24881819.

Joshi S, Singh AR, Zulcic M, Bao L, Messer K, Ideker T, Dutkowski J, Durden DL. Rac2 controls tumor growth, metastasis and M1-M2 macrophage differentiation in vivo. PLoS One. 2014 Apr 25;9(4):e95893. doi: 10.1371/journal.pone.0095893. PubMed PMID: 24770346; PubMed Central PMCID: PMC4000195.

Hartman LL, Crawford JR, Makale MT, Milburn M, Joshi S, Salazar AM, Hasenauer B, VandenBerg SR, MacDonald TJ, Durden DL. Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors. J Pediatr Hematol Oncol. 2014 Aug;36(6):451-7. doi: 10.1097/MPH.0000000000000047. PubMed PMID: 24309609; PubMed Central PMCID: PMC4356196.

Muh CR, Joshi S, Singh AR, Kesari S, Durden DL, Makale MT. PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1α suppression. J Neurooncol. 2014 Jan;116(1):89-97. doi: 10.1007/s11060-013-1283-3. PubMed PMID: 24162827; PubMed Central PMCID: PMC3896301.

Morales GA, Garlich JR, Su J, Peng X, Newblom J, Weber K, Durden DL. Synthesis and cancer stem cell-based activity of substituted 5-morpholino-7H-thieno[3,2-b]pyran-7-ones designed as next generation PI3K inhibitors. J Med Chem. 2013 Mar 14;56(5):1922-39. doi: 10.1021/jm301522m. PubMed PMID: 23410005.

De P, Dey N, Terakedis B, Bergsagel PL, Li ZH, Mahadevan D, Garlich JR, Trudel S, Makale MT, Durden DL. An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo. Cancer Chemother Pharmacol. 2013 Apr;71(4):867-81. doi: 10.1007/s00280-013-2078-0. PubMed PMID: 23355037; PubMed Central PMCID: PMC3832139.

Emmenegger BA, Hwang EI, Moore C, Markant SL, Brun SN, Dutton JW, Read TA, Fogarty MP, Singh AR, Durden DL, Yang C, McKeehan WL, Wechsler-Reya RJ. Distinct roles for fibroblast growth factor signaling in cerebellar development and medulloblastoma. Oncogene. 2013 Aug 29;32(35):4181-8. doi: 10.1038/onc.2012.440. PubMed PMID: 23045271; PubMed Central PMCID: PMC3808889.

Mahadevan D, Chiorean EG, Harris WB, Von Hoff DD, Stejskal-Barnett A, Qi W, Anthony SP, Younger AE, Rensvold DM, Cordova F, Shelton CF, Becker MD, Garlich JR, Durden DL, Ramanathan RK. Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. Eur J Cancer. 2012 Dec;48(18):3319-27. doi: 10.1016/j.ejca.2012.06.027. PubMed PMID: 22921184; PubMed Central PMCID: PMC3826796.

Peirce SK, Findley HW, Prince C, Dasgupta A, Cooper T, Durden DL. The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention. Cancer Chemother Pharmacol. 2011 Aug;68(2):325-35. doi: 10.1007/s00280-010-1486-7. PubMed PMID: 20972874; PubMed Central PMCID: PMC3143317.

Castellino RC, Barwick BG, Schniederjan M, Buss MC, Becher O, Hambardzumyan D, Macdonald TJ, Brat DJ, Durden DL. Heterozygosity for Pten promotes tumorigenesis in a mouse model of medulloblastoma. PLoS One. 2010 May 26;5(5):e10849. doi: 10.1371/journal.pone.0010849. PubMed PMID: 20520772; PubMed  Central PMCID: PMC2877103.

Crosswell HE, Dasgupta A, Alvarado CS, Watt T, Christensen JG, De P, Durden DL, Findley HW. PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells. BMC Cancer. 2009 Nov 25;9:411. doi: 10.1186/1471-2407-9-411. PubMed PMID: 19939254; PubMed Central PMCID: PMC2790467.

Ozbay T, Durden DL, Liu T, O'Regan RM, Nahta R. In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells. Cancer Chemother Pharmacol. 2010 Mar;65(4):697-706. doi: 10.1007/s00280-009-1075-9. PubMed PMID: 19636556; PubMed Central PMCID: PMC2808522.

Gu L, Zhu N, Zhang H, Durden DL, Feng Y, Zhou M. Regulation of XIAP translation and induction by MDM2 following irradiation. Cancer Cell. 2009 May 5;15(5):363-75. doi: 10.1016/j.ccr.2009.03.002. PubMed PMID: 19411066; PubMed Central PMCID: PMC2696306.

Rong Y, Belozerov VE, Tucker-Burden C, Chen G, Durden DL, Olson JJ, Van Meir EG, Mackman N, Brat DJ. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Cancer Res. 2009 Mar 15;69(6):2540-9. doi: 10.1158/0008-5472.CAN-08-1547. PubMed PMID: 19276385; PubMed Central PMCID: PMC2759716.

Castellino RC, Muh CR, Durden DL. PI-3 kinase-PTEN signaling node: an intercept point for the control of angiogenesis. Curr Pharm Des. 2009;15(4):380-8. Review. PubMed PMID: 19199965.

De P, Peng Q, Traktuev DO, Li W, Yoder MC, March KL, Durden DL. Expression of RAC2 in endothelial cells is required for the postnatal neovascular response. Exp Cell Res. 2009 Jan 15;315(2):248-63. Erratum in: Exp Cell Res. 2009 Oct 1;315(16):2869. Traktuevc, Dmitry O [corrected to Traktuev, Dmitry O]. PubMed PMID: 19123268; PubMed Central PMCID: PMC2767303.

Dey N, Crosswell HE, De P, Parsons R, Peng Q, Su JD, Durden DL. The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration. Cancer Res. 2008 Mar 15;68(6):1862-71. doi: 10.1158/0008-5472.CAN-07-1182. PubMed PMID: 18339867.

Garlich JR, De P, Dey N, Su JD, Peng X, Miller A, Murali R, Lu Y, Mills GB, Kundra V, Shu HK, Peng Q, Durden DL. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res. 2008 Jan 1;68(1):206-15. doi: 10.1158/0008-5472.CAN-07-0669. Erratum in: Cancer Res. 2008 Jul 15;68(1):6030. PubMed PMID: 18172313.

Li Y, Yan J, De P, Chang HC, Yamauchi A, Christopherson KW 2nd, Paranavitana NC, Peng X, Kim C, Munugalavadla V, Kapur R, Chen H, Shou W, Stone JC, Kaplan MH, Dinauer MC, Durden DL, Quilliam LA. Rap1a null mice have altered myeloid cell functions suggesting distinct roles for the closely related Rap1a and 1b proteins. J Immunol. 2007 Dec 15;179(12):8322-31. Erratum in: J Immunol. 2008 Mar 1;180(5):3612. Munugulavadla, Veerendra [corrected to Munugalavadla, Veerendra]. PubMed PMID: 18056377; PubMed Central PMCID: PMC2722108.

Castellino RC, Durden DL. Mechanisms of disease: the PI3K-Akt-PTEN signaling node--an intercept point for the control of angiogenesis in brain tumors. Nat Clin Pract Neurol. 2007 Dec;3(12):682-93. Review. PubMed PMID: 18046441.

Dey N, De PK, Wang M, Zhang H, Dobrota EA, Robertson KA, Durden DL. CSK controls retinoic acid receptor (RAR) signaling: a RAR-c-SRC signaling axis is required for neuritogenic differentiation. Mol Cell Biol. 2007 Jun;27(11):4179-97. PubMed PMID: 17325034; PubMed Central PMCID: PMC1900023.

Denning G, Jean-Joseph B, Prince C, Durden DL, Vogt PK. A short N-terminal sequence of PTEN controls cytoplasmic localization and is required for suppression of cell growth. Oncogene. 2007 Jun 7;26(27):3930-40. PubMed PMID: 17213812.

Reinert RB, Oberle LM, Wek SA, Bunpo P, Wang XP, Mileva I, Goodwin LO, Aldrich CJ, Durden DL, McNurlan MA, Wek RC, Anthony TG. Role of glutamine depletion in directing tissue-specific nutrient stress responses to L-asparaginase. J Biol Chem. 2006 Oct 20;281(42):31222-33. PubMed PMID: 16931516.

Rong Y, Hu F, Huang R, Mackman N, Horowitz JM, Jensen RL, Durden DL, Van Meir EG, Brat DJ. Early growth response gene-1 regulates hypoxia-induced expression of tissue factor in glioblastoma multiforme through hypoxia-inducible factor-1-independent mechanisms. Cancer Res. 2006 Jul 15;66(14):7067-74. PubMed PMID: 16849552; PubMed Central PMCID: PMC2610484.

Rong Y, Durden DL, Van Meir EG, Brat DJ. 'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol. 2006 Jun;65(6):529-39. Review. PubMed PMID: 16783163.

Dey N, Howell BW, De PK, Durden DL. CSK negatively regulates nerve growth factor induced neural differentiation and augments AKT kinase activity. Exp Cell Res. 2005 Jul 1;307(1):1-14. PubMed PMID: 15890337.

Rong Y, Post DE, Pieper RO, Durden DL, Van Meir EG, Brat DJ. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res. 2005 Feb 15;65(4):1406-13. PubMed PMID: 15735028.

Moon KD, Post CB, Durden DL, Zhou Q, De P, Harrison ML, Geahlen RL. Molecular basis for a direct interaction between the Syk protein-tyrosine kinase and phosphoinositide 3-kinase. J Biol Chem. 2005 Jan 14;280(2):1543-51. PubMed PMID: 15536084.

Pradip D, Peng X, Durden DL. Rac2 specificity in macrophage integrin signaling: potential role for Syk kinase. J Biol Chem. 2003 Oct 24;278(43):41661-9. PubMed PMID: 12917394.

Su JD, Mayo LD, Donner DB, Durden DL. PTEN and phosphatidylinositol 3'-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment. Cancer Res. 2003 Jul 1;63(13):3585-92. PubMed PMID: 12839945.

Erdreich-Epstein A, Tran LB, Bowman NN, Wang H, Cabot MC, Durden DL, Vlckova J, Reynolds CP, Stins MF, Groshen S, Millard M. Ceramide signaling in fenretinide-induced endothelial cell apoptosis. J Biol Chem. 2002 Dec 20;277(51):49531-7. PubMed PMID: 12388538.

Kant AM, De P, Peng X, Yi T, Rawlings DJ, Kim JS, Durden DL. SHP-1 regulates Fcgamma receptor-mediated phagocytosis and the activation of RAC. Blood. 2002 Sep 1;100(5):1852-9. PubMed PMID: 12176909.

Reiff A, Zastrow M, Sun BC, Takei S, Mitsuhada H, Bernstein B, Durden DL. Treatment of collagen induced arthritis in DBA/1 mice with L-asparaginase. Clin Exp Rheumatol. 2001 Nov-Dec;19(6):639-46. PubMed PMID: 11791634.

Kim JS, Peng X, De PK, Geahlen RL, Durden DL. PTEN controls immunoreceptor(immunoreceptor tyrosine-based activation motif) signaling and the activation of Rac. Blood. 2002 Jan 15;99(2):694-7. PubMed PMID: 11781256.

Mayo LD, Dixon JE, Durden DL, Tonks NK, Donner DB. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem. 2002 Feb 15;277(7):5484-9. PubMed PMID: 11729185.

Isogai C, Laug WE, Shimada H, Declerck PJ, Stins MF, Durden DL, Erdreich-Epstein A, DeClerck YA. Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin. Cancer Res. 2001 Jul 15;61(14):5587-94. PubMed PMID: 11454712.

Wen S, Stolarov J, Myers MP, Su JD, Wigler MH, Tonks NK, Durden DL. PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4622-7. PubMed PMID: 11274365; PubMed Central PMCID: PMC31884.

Erdreich-Epstein A, Shimada H, Groshen S, Liu M, Metelitsa LS, Kim KS, Stins MF, Seeger RC, Durden DL. Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Res. 2000 Feb 1;60(3):712-21. PubMed PMID: 10676658.

Park RK, Erdreich-Epstein A, Liu M, Izadi KD, Durden DL. High affinity IgG receptor activation of Src family kinases is required for modulation of the Shc-Grb2-Sos complex and the downstream activation of the nicotinamide adenine dinucleotide phosphate (reduced) oxidase. J Immunol. 1999 Dec 1;163(11):6023-34. PubMed PMID: 10570290.

Park RK, Izadi KD, Deo YM, Durden DL. Role of Src in the modulation of multiple adaptor proteins in FcalphaRI oxidant signaling. Blood. 1999 Sep 15;94(6):2112-20. PubMed PMID: 10477741.

Erdreich-Epstein A, Liu M, Kant AM, Izadi KD, Nolta JA, Durden DL. Cbl functions downstream of Src kinases in Fc gamma RI signaling in primary human macrophages. J Leukoc Biol. 1999 Apr;65(4):523-34. PubMed PMID: 10204582.

Izadi KD, Erdreich-Epstein A, Liu Y, Durden DL. Characterization of Cbl-Nck and Nck-Pak1 interactions in myeloid FcgammaRII signaling. Exp Cell Res. 1998 Dec 15;245(2):330-42. PubMed PMID: 9851874.

Kyono WT, de Jong R, Park RK, Liu Y, Heisterkamp N, Groffen J, Durden DL. Differential interaction of Crkl with Cbl or C3G, Hef-1, and gamma subunit immunoreceptor tyrosine-based activation motif in signaling of myeloid high affinity Fc receptor for IgG (Fc gamma RI). J Immunol. 1998 Nov 15;161(10):5555-63. PubMed PMID: 9820532.

Chu J, Liu Y, Koretzky GA, Durden DL. SLP-76-Cbl-Grb2-Shc interactions in FcgammaRI signaling. Blood. 1998 Sep 1;92(5):1697-706. PubMed PMID: 9716598.

Park RK, Kyono WT, Liu Y, Durden DL. CBL-GRB2 interaction in myeloid immunoreceptor tyrosine activation motif signaling. J Immunol. 1998 May 15;160(10):5018-27. PubMed PMID: 9590251.

Erdreich-Epstein A, Liu M, Liu Y, Durden DL. Protein tyrosine phosphatase inhibitors in Fc gamma RI-induced myeloid oxidant signaling. Exp Cell Res. 1997 Dec 15;237(2):288-95. PubMed PMID: 9434624.

Taylor N, Jahn T, Smith S, Lamkin T, Uribe L, Liu Y, Durden DL, Weinberg K. Differential activation of the tyrosine kinases ZAP-70 and Syk after Fc gamma RI stimulation. Blood. 1997 Jan 15;89(2):388-96. PubMed PMID: 9002939.

Park RK, Liu Y, Durden DL. A role for Shc, Grb2, and Raf-1 in FcgammaRI signal relay. J Biol Chem. 1996 Jun 7;271(23):13342-8. PubMed PMID: 8662746.

Arditi M, Zhou J, Torres M, Durden DL, Stins M, Kim KS. Lipopolysaccharide stimulates the tyrosine phosphorylation of mitogen-activated protein kinases p44, p42, and p41 in vascular endothelial cells in a soluble CD14-dependent manner. Role of protein tyrosine phosphorylation in lipopolysaccharide-induced stimulation of endothelial cells. J Immunol. 1995 Oct 15;155(8):3994-4003. PubMed PMID: 7561108.

Durden DL, Kim HM, Calore B, Liu Y. The Fc gamma RI receptor signals through the activation of hck and MAP kinase. J Immunol. 1995 Apr 15;154(8):4039-47. PubMed PMID: 7535819.

Durden DL, Liu YB. Protein-tyrosine kinase p72syk in Fc gamma RI receptor signaling. Blood. 1994 Oct 1;84(7):2102-8. PubMed PMID: 7522622.

Durden DL, Rosen H, Cooper JA. Serine/threonine phosphorylation of the gamma-subunit after activation of the high-affinity Fc receptor for immunoglobulin G. Biochem J. 1994 Apr 15;299 ( Pt 2):569-77. PubMed PMID: 8172619; PubMed Central PMCID: PMC1138309.

Durden DL, Rosen H, Michel BR, Cooper JA. Protein tyrosine phosphatase inhibitors block myeloid signal transduction through the Fc gamma RI receptor. Exp Cell Res. 1994 Mar;211(1):150-62. PubMed PMID: 8125152.

Kazlauskas A, Durden DL, Cooper JA. Functions of the major tyrosine phosphorylation site of the PDGF receptor beta subunit. Cell Regul. 1991 Jun;2(6):413-25. PubMed PMID: 1653029; PubMed Central PMCID: PMC361823.

Durden DL, Salazar AM, Distasio JA. Kinetic analysis of hepatotoxicity associated with antineoplastic asparaginases. Cancer Res. 1983 Apr;43(4):1602-5. PubMed PMID: 6339039.

Distasio JA, Salazar AM, Nadji M, Durden DL. Glutaminase-free asparaginase from vibrio succinogenes: an antilymphoma enzyme lacking hepatotoxicity. Int J Cancer. 1982 Sep 15;30(3):343-7. PubMed PMID: 6752048.

Distasio JA, Durden DL, Paul RD, Nadji M. Alteration in spleen lymphoid populations associated with specific amino acid depletion during L-asparaginase treatment. Cancer Res. 1982 Jan;42(1):252-8. PubMed PMID: 7032693.

Durden DL, Distasio JA. Characterization of the effects of asparaginase from Escherichia coli and a glutaminase-free asparaginase from Vibrio succinogenes on specific ell-mediated cytotoxicity. Int J Cancer. 1981 Jan 15;27(1):59-65. PubMed PMID: 7019106.

Durden DL, Distasio JA. Comparison of the immunosuppressive effects of asparaginases from Escherichia coli and Vibrio succinogenes. Cancer Res. 1980 Apr;40(4):1125-9. PubMed PMID: 6986981.

Charyulu V, Sigel MM, Durden DL, Lopez DM. Mouse mammary tumor virus (MMTV) antigen(s) are present on B lymphocytes of BALB/c mice. Int J Cancer. 1979 Dec 15;24(6):813-8. PubMed PMID: 94593.